Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
VIPS Vipshop Holdings Ltd
CAT Caterpillar Inc
AAPL Apple Inc
ESLT Elbit Systems Ltd
AZO Autozone Inc
DITTF Daito Trust Construction Co Ltd
MYO Myomo Inc
CRVS Corvus Pharmaceuticals Inc

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.


Last Trade
0.11 (0.08%)
B/A Size

Market Hours

Closing Price
Day's Change
0.33 (0.23%)
B/A Size
Day's High
Day's Low
(Above Average)

10-day average volume:

UPDATE: HPE is undertaking another reorganization after a lousy quarter, to the chagrin of analysts

3:49 pm ET May 22, 2020 (MarketWatch)

By Jon Swartz

Hewlett Packard Enterprise Co. has been down this restructuring road before.

In announcing a three-year "Cost Optimization and Prioritization Plan" Thursday to save more than $1 billion after a lousy quarter hit by the COVID-19 pandemic, executives of the information technology company (HPE) announced their latest scheme to cut costs -- much to the chagrin of Wall Street analysis.

HPE shares are down 11% at midsession Friday.

See also: HPE loses more than $800 million as sales slump, CEO blames coronavirus 'economic lockdowns' (

A.B. Bernstein analyst Toni Sacconaghi, who pointedly pressed HPE Chief Executive Antonio Neri on the topic, led the skepticism during a conference call with analysts late Thursday. Subsequently, several analysts expressed frustration over yet another organizational reboot in some stinging notes.

"Another Re-Organization, Further Reducing Footprint, Still No Product Story," Susquehanna International Group's Mehdi Hosseini lamented in a note that retained a neutral rating and price target to $10. He is one of at least 10 analysts who have reduced their price target on HPE since March and the spread of COVID-19.

HPE reported ( a loss of $821 million, or 64 cents a share, on revenue of $6.01 billion, down 16% from $7.15 billion a year ago. After adjustments for an $865 million impairment charge and other effects, the company reported earnings of 22 cents a share, down from adjusted earnings of 42 cents a share a year ago. Analysts surveyed by FactSet had expected adjusted earnings of 30 cents a share on sales of $6.33 billion.

The company, which pointed to supply chain constraints as part of the problem, offered no financial guidance for the current quarter or fiscal year.

Neri, who attributed a downturn in sales last year to lowered IT demand, has overseen some cost-cutting plan or another since he succeeded Meg Whitman as CEO in November 2017. Two months earlier, Whitman said the company had the opportunity to create a structure and operating model that is "simpler, nimbler and faster," and it will begin a program called HPE Next to "simplify how we work."

See also: Opinion: HP Enterprise has yet another confusing plan to simplify itself (

Ongoing efforts to pare costs haven't led to a bounce in profits or HPE's stock. It's down 42% in 2020, and more than half since March 9, 2018. The S&P 500 index is down 9% this year but up 5.5% since March 9, 2018.

"HPE Next 2.0 -- Will This Be Any Different?" groused Evercore ISI analyst Amit Daryanani, who remains steady on HPE stock with an inline rating and $11 price target.

"The risk here could be that HPE needs to execute an aggressive cost reduction plan to stabilize their opex run-rate in light of a muted revenue expectation given accelerated shift towards a cloud first environment and uptick in competition from DELL (DELL) and Lenovo," Daryanani wrote late Thursday.

The outlook was dire enough for Barclays' Tim Long to lower his earnings per share estimate for FY20/F21 from $1.38/$1.40 to $1.16/$1.29. HPE did not offer guidance for its current quarter or fiscal year. Consequently, Long lowered his price target on HPE to $9 from $10, based on an unchanged PE multiple of 7x our FY21 EPS estimate. Long maintains an equal weight rating.

There was a ray of optimism from RBC Capital Markets' Robert Muller. He believes HPE's rising backlog could "provide a tailwind as HPE unwinds its order book (if cancellations do not occur)". And he noted a "modest" revenue decline of 2% for Intelligent Edge, the company's data-analysis tool, to $665 million with operating margins of 11% -- above his 6.5% estimate.

Nonetheless, he remains cautious for now because of uncertainty over COVID-19 and a difficult sales environment. Muller maintains a perform rating on HPE shares with a price target of $11.

Hewlett Packard Enterprise was founded in November 2015 as part of the splitting of the original Hewlett-Packard company. The split was structured so that the former Hewlett-Packard Company changed its name HP Inc. (HPQ) and retained the old HP's personal computer and printing business, while the newly created company HPE focused on servers, storage, networking, consulting and support.

-Jon Swartz; 415-439-6400;

(END) Dow Jones Newswires

May 22, 2020 15:49 ET (19:49 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.